Krebs Biochemicals & Industries Limited

Agriculture Medicine Product

	Fact Sheet Year of Establishment : 1991 Legal Status of Firm : Limited Liability/Corporation (Listed Company) Nature of Business : Manufacturer Number of Employees : 101 to 500 People Turnover : US$ 25-100 Million (or Rs. 100-400 Crore Approx.) Major Markets : Indian Subcontinent

Quality

So far the following were achieved by the organisation from various international accredited bodies ISO 9002 in November 2001. ISO 9001: 2000 in March 2004 EDQM July 2003 USFDA in November 2003 WHO GMP certification in November 2002 and renewed in March 2005.

NEWS

 [29-APR-04]
Krebs Biochemicals & Industries Limited is a biochemical company engaged in manufacture of active Pharmaceutical ingredients with its product portfolio comprising of Statins (lifestyle drugs), Neutraceuticals and anti-asthmatic groups and has pioneered in the fermentation technology.

Audited financial results for the Year 2003-04

During the year under review, the company has achieved a turnover of Rs. 101.23 Crores as against 101.50 crores in the previous year with a gross profit of Rs. 30.71 Crores and net profit of Rs. 13.51 crores as against Rs.29.38 Crores and Rs.14.87 Crores respectively in the previous year. The profitability is affected mainly on account of slowdown in the movement of anti asthmatic segment drugs, namely ephedrine and pseudoephedrine and increase in the raw material costs (Molasses) and drop in the sales price of some of the products. With the substantial restructuring of the plant at Unit II at Kothapalli (Vizag), the turnover has increased significantly from Rs. 32.45 Crores previous year to Rs.49.90 Crores in the current year.

During the year under review the company has achieved an EPS of Rs. 22.52 as against Rs.24.79 in the previous year. The Board has recommended a dividend of Rs.8.00 per share on a paid up capital of Rs. 6.00 crores.

Consolidation:

During the last 10 Years, the company has witnessed substantial growth in the turnover both export and domestic with good profitability and dividend payment record and consolidated its position as one among the top 10 Big Pharmaceutical companies.

Diversification Plans:

Having consolidated in the current line of activity, the company has initiated steps to diversify into other activities. In this direction the company has identified bio fuels and it's down stream products to catalyze the growth. The company was successful bidder for the Jampani and Kovur co-operative sugar mills and completed the crushing operations in the Jampani Unit for the crushing season 2003-04. However, the handing over the possession of the Kovur Unit is yet to be completed. The company has also diversified into food products by setting up of stackable potato chips unit with a capacity of 1800 MT per annum. The commercial operations will commence in the 2nd Quarter of the current financial Year. The company is aiming to achieve a turnover of Rs. 200 crores in the current year 2004-05 with a net profit of Rs.30 crores. With all the major expansion & diversification projects coming to fruition during the 1st quarter of current year, these targets are quite achievable.

 [31-MAR-05]
Krebs Biochemicals & Industries Limited is a biochemical company engaged in manufacture of active Pharmaceutical ingredients with its product portfolio comprising of Statins (lifestyle drugs), Neutraceuticals and anti-asthmatic groups and has pioneered in the fermentation technology.

Audited financial results for the Year 2004-05

During the year under review, the company has achieved a turnover of Rs. 79.26 Crores as against 101.23 crores in the previous year with a gross profit of Rs. 27.69 Crores and net profit of Rs. 7.43 crores as against Rs.30.71 Crores and Rs.13.51 Crores respectively in the previous year. The profitability is affected mainly on account of slowdown in the movement of anti asthmatic segment drugs, namely ephedrine and pseudoephedrine and increase in the raw material costs (Molasses) and drop in the sales price of some of the products. As the existing facilities at Unit II at Kothapalli (Vizag) were under modification to suit to the requirement of USFDA, production of Lovastatin and Simvastatin had been reduced to a nominal quantity during the last quarter.

During the year under review the company has achieved an EPS of Rs. 12.39 as against Rs.22.52 in the previous year. The Board has recommended a dividend of Rs.3.00 per share on a paid up capital of Rs. 6.00 crores.

Future outlook:

To cope up with USFDA requirement, the plant at Vizag has been renewed/modified, which improves the turnover and profitability of the company. As far as Unit I at Nellore is concerned, the Company is working out to enter into Manufacturing Contract (Outsourcing) tie ups with some of the reputed multinational companies, which will help the company not only to improve its turnover and profitability but also to utilize the Plant at its full capacity.

Diversification Plans:

Having consolidated in the current line of activity, the company has initiated steps to diversify into other activities. In this direction the company has identified bio fuels and it's down stream products to catalyze the growth.

The company was successful bidder for the Jampani and Kovur co-operative sugar mills and completed the crushing operations in the Jampani Unit for the crushing season 2003-04. However, as per the directions of the Hon'ble High Court of Andhra Pradesh vide its order dated 29.06.2004, the Government of Andhra Pradesh has restored the management of the Jampani Sugar Factory to the erstwhile managing committee of the society.

Contact Details

Company Name: Krebs Biochemicals & Industries Limited Contact Person: Mr. Satish Telephone: +(91)-(40)-44707752 Fax No: +(91)-(40)-44705555 Address: Banjara Hills, Road No. 2,Inwinex Towers, Plot No. 130, 4th Floor, Hyderabad, Andhra Pradesh - 500034 (India)